Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone

MLA

Dirkje W. Sommeijer, et al. Molecular Subtype-Specific Efficacy of Anti-EGFR Therapy in Colorectal Cancer Is Dependent on the Chemotherapy Backbone. July 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....329765bd38bc4fb86b004b51f8c16428&authtype=sso&custid=ns315887.

APA

Dirkje W. Sommeijer, Matthew T. Seymour, Lianne Koens, Cornelis J. A. Punt, Sanne ten Hoorn, David Fisher, Tim Maughan, Louis Vermeulen, Faye Elliott, Anne Trinh, Phil Quirke, Susan D. Richman, Jenny F. Seligmann, Tim R. de Back, & Richard Adams. (2021). Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone.

Chicago

Dirkje W. Sommeijer, Matthew T. Seymour, Lianne Koens, Cornelis J. A. Punt, Sanne ten Hoorn, David Fisher, Tim Maughan, et al. 2021. “Molecular Subtype-Specific Efficacy of Anti-EGFR Therapy in Colorectal Cancer Is Dependent on the Chemotherapy Backbone,” July. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....329765bd38bc4fb86b004b51f8c16428&authtype=sso&custid=ns315887.